Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
about
sameAs
The McNemar test for binary matched-pairs data: mid-p and asymptotic are better than exact conditionalBortezomib for the treatment of multiple myelomaEfficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-AnalysisTreatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answersEuropean perspective on multiple myeloma treatment strategies in 2014New criteria for response assessment: role of minimal residual disease in multiple myelomaRecent advances in understanding multiple myelomaOptimal maintenance and consolidation therapy for multiple myeloma in actual clinical practiceAdvances in understanding prognosis in myeloma.The role of SLAMF7 in multiple myeloma: impact on therapy.Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma.Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma.Consolidation in multiple myeloma - current status and perspectivesTrends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma.Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients.Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 studyElectroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study.Bortezomib in multiple myeloma: systematic review and clinical considerations.Immunomodulatory drugs in multiple myeloma.Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple MyelomaDilemmas in treating smoldering multiple myeloma.Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma.Haematopoietic stem cell transplantation as first-line treatment in myeloma: a global perspective of current concepts and future possibilitiesLipopolysaccharide-Induced CXCL10 mRNA Level and Six Stimulant-mRNA Combinations in Whole Blood: Novel Biomarkers for Bortezomib Responses Obtained from a Prospective Multicenter Trial for Patients with Multiple Myeloma.Bortezomib-based vs non-bortezomib-based post-transplantation treatment in multiple myeloma patients: a systematic review and meta-analysis of Phase III randomized controlled trialsCD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma.Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma.Single-agent bortezomib or bortezomib-based regimens as consolidation therapy after autologous hematopoietic stem cell transplantation in multiple myeloma: a meta-analysis of randomized controlled trialsOutcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell TransplantationDiagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion.Efficient allocation of novel agents in multiple myeloma: a work in progressBortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial.The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.Phytohemagglutinin-induced IL2 mRNA in whole blood can predict bortezomib-induced peripheral neuropathy for multiple myeloma patients.A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma.Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies.
P2860
Q21261932-CB432584-9EFD-4123-B84C-E28AED735F42Q24185881-45F2BEBB-FD15-4353-B05F-B58D6DD91EB1Q26767418-0E0AD7DA-3420-438F-9656-98A5BFEACB85Q26851202-4E3094DE-CDE7-4C78-A323-F8B7FF072D16Q27005966-7CE9A40E-2C7C-4B2E-BFED-6356D8DD79D2Q27027512-1C444778-7F9A-4B0C-B58D-40D8C99A087FQ28070331-C86BB444-D8E9-40FA-BE40-28F6E4391233Q28077567-DDE1E66C-895C-4F69-9C14-353597A596C6Q30244061-B90CE115-9CAC-423C-BFC2-86DC0A82539AQ30249167-7DA5F35A-960C-497C-920A-E3F34EB1FD97Q30275382-E21216C8-EF17-4384-B7E6-9FDBCF929750Q30313340-EBF49625-48DE-49B0-A751-200CADD1430EQ30369423-9613D6A9-B9D0-4305-BB0F-FEE93F68B0FEQ30409713-EE49493C-4F24-4F59-9CD4-06CF43561DE3Q33415911-817200EC-82A5-4A39-B61C-57D0E3ED9BC6Q33425607-B3ABBC59-0B39-4A16-A82C-96526FF8478CQ33684190-0E3584A5-4A23-447A-9592-247F2C74D902Q33982728-7A75F904-5DE0-4844-B37C-9BEC4F7AECBEQ34325722-0D48D1DF-96B4-42C5-B74B-C04ADF142F60Q34380489-871131B8-DD44-4990-8A52-48C86D65C3B7Q34694749-FE7FD9B8-BA3B-43D2-8BCA-D06B8DB4828CQ34716500-C1533BD0-EF0F-4253-A597-70F1D8AE886FQ34990174-199CF47D-F747-4B10-A8C4-4FF5C1CF6790Q35569350-F956AD28-59E9-4E97-BC74-7A77672E4434Q35675837-DCCCF81E-F038-45A8-997A-54EEDC2F3E15Q35760754-07BD0A63-AFE0-4B8D-AD27-8A92CB08091BQ35886785-3EC19287-632E-4999-88F0-2BA2E2BF59B6Q36051084-CCA7EFCC-9443-49F7-8D0F-7D977969FA8EQ36182653-0EBB7E62-D435-474B-B3FA-32F589868812Q36279610-6A77F101-CC5E-4D2A-B223-FC968712BEDEQ36301287-51707D1B-B2EC-4B5A-92EF-866F73F7D0DCQ36565638-9F84B9BD-1A19-4031-9154-927AEE3C3573Q36592788-A1A14668-4633-47EB-A6A5-88C29AA3E5BDQ36595290-6D75E6D2-6197-4079-B469-225DE9B2A65CQ36907828-B43F2F01-F60C-4838-A68A-B8EF3B72F33BQ36962747-F8398C30-DF30-47AC-AC33-67D39E6A7BFAQ37037265-D1563CA1-459D-4D8F-B4C5-BB7504B92074Q37275721-9B911964-4353-4352-8F29-2D5E1C124186Q37373159-4281FF10-21EC-4283-B58E-6166B905E39BQ37373269-89401DFA-E0DE-48A4-9691-A04B5B2992BD
P2860
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
description
im Juli 2012 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 12 April 2012
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в липні 2012
@uk
name
Bortezomib-thalidomide-dexamet ...... wly diagnosed multiple myeloma
@en
Bortezomib-thalidomide-dexamet ...... wly diagnosed multiple myeloma
@nl
type
label
Bortezomib-thalidomide-dexamet ...... wly diagnosed multiple myeloma
@en
Bortezomib-thalidomide-dexamet ...... wly diagnosed multiple myeloma
@nl
prefLabel
Bortezomib-thalidomide-dexamet ...... wly diagnosed multiple myeloma
@en
Bortezomib-thalidomide-dexamet ...... wly diagnosed multiple myeloma
@nl
P2093
P50
P1433
P1476
Bortezomib-thalidomide-dexamet ...... wly diagnosed multiple myeloma
@en
P2093
Andrea Nozza
Angelo Michele Carella
Anna Baraldi
Anna Furlan
Annalisa Pezzi
Antonietta Falcone
Catello Califano
Chiara Nozzoli
Claudia Crippa
Daniela Donnarumma
P356
10.1182/BLOOD-2012-02-408898
P407
P577
2012-04-12T00:00:00Z